The objective of the present study was to explore the possibility of applying patient-specific hiLOs from hiPSC-derived NKX2.1+ lung progenitors and hiBCs to assess the effectiveness of pathogenetic therapy for cystic fibrosis and evaluate the accuracy of the FIS assay for hiLOs by carrying out ROC analysis. This evidence concerns the gene NKX2-1 and cystic fibrosis.